<DOC>
	<DOC>NCT01135602</DOC>
	<brief_summary>12-week, open-label study of topiramate in hospitalized patients with alcoholism</brief_summary>
	<brief_title>Topiramate for Hospitalized Patients With Alcoholism: a 12-week Study</brief_title>
	<detailed_description />
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Topiramate</mesh_term>
	<criteria>Patients hospitalized due to alcoholrelated problems DSMIVTR alcohol dependence &gt;/= 35 drinks/week (male) or &gt;/= 28 drinks/week (female) for &gt;/= 1 week during four weeks prior to the admission AUDIT score &gt;/= 8 Mild or no alcohol withdrawal Body mass index &gt; 18 kg/m2 No pregnancy and no plan for pregnancy (female) Intention to decrease or stop drinking Severe psychiatric and cognitive disorders Other substance dependence, except nicotine and caffeine dependence, during 6 months prior to enrollment Taking antipsychotics, mood stabilizers, anticonvulsants, opioid analgesics, systematic steroids, carbonic anhydrase inhibitors, hydrochlorthiazide, metformin, pioglitazone, or disulfiram Moderate to high risk of suicide Medical history of narrow angle glaucoma, renal impairment, kidney stones, and seizures Unstable medical conditions Plan to receive a formal treatment for alcoholism from other treatment settings Under legal process Pregnancy and nursing woman Abnormal laboratory tests, including blood urea nitrogen, creatinine, electrolytes, and fasting blood sugar</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>June 2010</verification_date>
	<keyword>Alcohol dependence</keyword>
	<keyword>Alcoholism</keyword>
	<keyword>Topiramate</keyword>
</DOC>